Acurx Pharmaceuticals, Inc. Common Stock
ACXPStock
$1.59−81.91%52W
Market Cap$7.52M
P/E—
Div yield—
Beta-2.05
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-52.17%
Price vs S&P 500 (4W)5.49%
VGM Score26.97
Market Capitalization$7.52M
Earnings Surprise History
Q1 26-0.62est. -0.65
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACXPAcurx Pharmaceuticals, Inc. Common Stock | — | — | D | $1.59 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel antibiotics for serious infections caused by priority pathogens identified by the WHO, CDC, and FDA. The company's platform targets Gram-positive bacteria and includes both clinical and preclinical drug candidates.